L
LequteMan
Guest
Top pharmaceutical company, Merck, has joined the fight against Ebola virus by signing a vaccine licensing deal with an Iowa firm, Medical Xpress reports.
Excerpt:
Merck, based in Whitehouse Station, New Jersey, said Monday it has entered a global partnership with a small U.S. drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing.
The exclusive deal involves rVSV-EBOV, a vaccine candidate under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of Ames, Iowa.
It was created in labs of the Public Health Agency of Canada, which in 2010 signed a deal giving BioProtection Systems an exclusive license for the vaccine and the technology for producing it.
click here to read more
#Merck #Ebola #NewLink
Excerpt:
Merck, based in Whitehouse Station, New Jersey, said Monday it has entered a global partnership with a small U.S. drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing.
The exclusive deal involves rVSV-EBOV, a vaccine candidate under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of Ames, Iowa.
It was created in labs of the Public Health Agency of Canada, which in 2010 signed a deal giving BioProtection Systems an exclusive license for the vaccine and the technology for producing it.
click here to read more
#Merck #Ebola #NewLink